Article
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
Leukemia - 1 Jan 2014
Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A M, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe C L, Sekeres M A, Advani A S, Kalaycio M, Copelan E A, Saunthararajah Y, Olalla Saad S T, Maciejewski J P, Tiu R V
Abstract excerpt
We hypothesized that specific molecular mutations are important biomarkers for response to DNA methyltransferase inhibitors (DNMT inhibitors) and may have prognostic value in patients with myelodysplastic syndromes (MDS). Mutational analysis was performed in 92 patients with MDS and related disorders who received 5-azacytidine (n=55), decitabine (n=26) or both (n=11). Mutational status was correlated with overall...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.